Britain and America have announced a key trade agreement that will keep no import taxes on British pharmaceutical products going into the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to raise spending on pharmaceuticals through the NHS. This pledge secures that duties on these key goods will be held at nothing for a timeframe of the next three years.
This agreement comes after recent statements to significantly raise import taxes on branded drug imports, with increases mentioned as high as 100%.
"This agreement between the United Kingdom strengthens the worldwide climate for new treatments and establishes much-needed fairness to transatlantic pharmaceutical trade," a statement noted.
Economic Importance
Medicines represent one of the the United Kingdom's largest exports to the United States, which is clearly the largest market for major UK drugmakers.
Trade data show that in the one-year period leading up to September, the UK shipped pharmaceutical products valued at billions to the US. This figure represented nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards employment, increases funding and paves the way for the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Key UK Commitments
The pact includes several notable changes from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to raise total health service expenditure on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The amount drug companies must return to the NHS to control costs will be capped at fifteen percent. Last year, refunds were more than 20%.
Recent Tensions
The pact follows a protracted dispute between the drug companies and the ministers over medicine costs and NHS adoption.
This friction were intensified by claims that American customers were charged a premium for the same drugs than patients in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar funding commitments have been pledged toward US facilities.
One official publicly accepted that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had declined as a proportion of its total funding over the previous ten-year period.
